Cogent Biosciences to Present KRAS and ErbB2 Research Data at AACR Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy COGT?
Cogent Biosciences announced that preclinical data from the Company's KRAS and ErbB2 pipeline programs will be presented during poster sessions at the American Association for Cancer Research, AACR, Annual Meeting 2026 taking place in April 17-22 in San Diego, CA. Title: Characterization of CGT1263, a KRAS inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS. preclinical poster highlights Cogent's internally developed pan-KRAS(ON) inhibitor with greater than500x selectivity for KRAS over HRAS and NRAS. Overall, these findings suggest CGT1263 could provide an advantage for patients, enabling higher dosing designed to elicit a more profound molecular response. Investigational New Drug enabling studies are ongoing with an IND submission expected later this year. Title: Preclinical characterization of CGT4255, an EGFR sparing, pan-mutant HER2 clinical development candidate with potential best-in-class brain penetration. Cogent's EGFR-sparing, brain-penetrant ErbB2 inhibitor includes potent coverage of key mutations inadequately addressed by currently approved therapies. Activating mutations in the ErbB2 gene have been identified in multiple cancers and demonstrate a tumorigenic role similar to that of ErbB2 amplification.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COGT
Wall Street analysts forecast COGT stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 37.250
Low
34.00
Averages
50.36
High
67.00
Current: 37.250
Low
34.00
Averages
50.36
High
67.00
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cogent Biosciences Completes NDA Submission for Bezuclastinib
- NDA Submission: Cogent Biosciences has completed its New Drug Application (NDA) submission for Bezuclastinib targeting patients with Gastrointestinal Stromal Tumors (GIST) previously treated with Imatinib, marking a significant advancement in oncology treatment.
- Clinical Trial Results: The NDA submission is based on positive outcomes from the PEAK trial, which demonstrated a 50% reduction in the risk of disease progression or death on the primary endpoint of progression-free survival (PFS) when Bezuclastinib was combined with Sunitinib compared to the current standard of care, indicating substantial clinical benefits.
- Strong Financial Position: As of December 30, 2025, Cogent reported cash, cash equivalents, and marketable securities totaling $900.8 million, which is expected to fund operations through 2028, showcasing robust financial backing for its R&D efforts.
- Upcoming Milestones: Cogent plans to present full results from the PEAK trial at a major medical meeting in the first half of 2026 and aims to submit another NDA for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) during the same period, further advancing its product pipeline.
See More
Cogent Biosciences Submits New Drug Application
- Stock Decline: Cogent Biosciences (COGT) shares are down approximately 6% in Wednesday morning trading, currently priced at $35.86, reflecting a $2.63 drop from the previous close of $38.50, indicating market caution regarding the new drug application.
- New Drug Application Submission: The company submitted a New Drug Application for bezuclastinib targeting patients with Gastrointestinal Stromal Tumors, based on positive findings from the PEAK trial, which suggest the drug's potential efficacy.
- FDA Review Process: This NDA was submitted under the FDA's Real-Time Oncology Review program, indicating the company's intent to expedite the approval process to bring the new drug to market sooner to meet patient needs.
- Historical Trading Range: Over the past year, Cogent Biosciences' stock has fluctuated between $3.72 and $43.73, and the current decline in stock price may affect investor confidence in the company's future prospects.
See More
RTW Investments Increases Stake in Cogent Biosciences Significantly
- Stake Increase: RTW Investments disclosed a significant purchase of 4,124,755 shares in Cogent Biosciences in its SEC filing dated February 17, 2026, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future.
- Market Value Growth: Following this purchase, Cogent's quarter-end position value rose to $219.88 million, reflecting optimistic market expectations regarding its potential in the precision medicine sector, particularly for genetically defined diseases.
- Portfolio Dynamics: RTW's stake in Cogent now represents 2.7% of its 13F reportable AUM, while its top holdings like MDGL and INSM also show robust market performance, highlighting the diversity of its investment strategy.
- Clinical Success Outlook: Cogent Biosciences' stock price surged 360% over the past year, and with its lead candidate's FDA application accepted, a crucial decision is expected by late 2026, which could further propel the stock's upward trajectory.
See More
RTW Investments Increases Stake in Cogent Biosciences
- Share Increase Details: RTW Investments added 4,124,755 shares of Cogent Biosciences in Q4 2026, with an estimated trade value of $115.95 million, indicating strong confidence in the company's future prospects.
- Holding Value Growth: By quarter-end, RTW's total holdings reached 7,592,241 shares valued at $269.68 million, reflecting a $219.88 million increase, which underscores market recognition and appreciation of Cogent's stock.
- Company Financial Health: Cogent Biosciences ended the year with approximately $900 million on its balance sheet, providing sufficient runway into 2028 while advancing multiple regulatory filings related to its lead drug, showcasing its robust R&D capabilities.
- Market Outlook Analysis: Despite a 360% surge in Cogent's stock price, its competitive edge in precision medicine and upcoming FDA decisions could yield substantial returns for investors, indicating significant future growth potential.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48.38 Million
- Share Reduction Details: Kynam Capital disclosed in a February 17, 2026 SEC filing that it sold 1,720,949 shares of Cogent Biosciences, translating to an estimated $48.38 million trade, indicating a disciplined approach to risk management while maintaining a significant position.
- Asset Management Proportion: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, remaining the fund's largest single position, which reflects ongoing confidence in the company's growth potential despite the reduction.
- Market Performance: As of last Friday, shares of Cogent Biosciences were priced at $33.38, having surged 360% over the past year, significantly outperforming the S&P 500's 15% gain, highlighting its strong market presence and investor interest in the biotech sector.
- Financial Status and Outlook: Cogent ended 2022 with $900.8 million in cash and equivalents, sufficient to fund operations into 2028, while its product bezuclastinib received FDA acceptance, with a target action date of December 30, further bolstering market confidence in its future prospects.
See More
Cogent Biosciences Completes NDA Submission for Bezuclastinib
- NDA Submission: Cogent Biosciences has completed its New Drug Application (NDA) submission for Bezuclastinib targeting patients with Gastrointestinal Stromal Tumors (GIST) previously treated with Imatinib, marking a significant advancement in oncology treatment.
- Clinical Trial Results: The NDA submission is based on positive outcomes from the PEAK trial, which demonstrated a 50% reduction in the risk of disease progression or death on the primary endpoint of progression-free survival (PFS) when Bezuclastinib was combined with Sunitinib compared to the current standard of care, indicating substantial clinical benefits.
- Strong Financial Position: As of December 30, 2025, Cogent reported cash, cash equivalents, and marketable securities totaling $900.8 million, which is expected to fund operations through 2028, showcasing robust financial backing for its R&D efforts.
- Upcoming Milestones: Cogent plans to present full results from the PEAK trial at a major medical meeting in the first half of 2026 and aims to submit another NDA for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) during the same period, further advancing its product pipeline.
See More
Cogent Biosciences Submits New Drug Application
- Stock Decline: Cogent Biosciences (COGT) shares are down approximately 6% in Wednesday morning trading, currently priced at $35.86, reflecting a $2.63 drop from the previous close of $38.50, indicating market caution regarding the new drug application.
- New Drug Application Submission: The company submitted a New Drug Application for bezuclastinib targeting patients with Gastrointestinal Stromal Tumors, based on positive findings from the PEAK trial, which suggest the drug's potential efficacy.
- FDA Review Process: This NDA was submitted under the FDA's Real-Time Oncology Review program, indicating the company's intent to expedite the approval process to bring the new drug to market sooner to meet patient needs.
- Historical Trading Range: Over the past year, Cogent Biosciences' stock has fluctuated between $3.72 and $43.73, and the current decline in stock price may affect investor confidence in the company's future prospects.
See More
RTW Investments Increases Stake in Cogent Biosciences Significantly
- Stake Increase: RTW Investments disclosed a significant purchase of 4,124,755 shares in Cogent Biosciences in its SEC filing dated February 17, 2026, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future.
- Market Value Growth: Following this purchase, Cogent's quarter-end position value rose to $219.88 million, reflecting optimistic market expectations regarding its potential in the precision medicine sector, particularly for genetically defined diseases.
- Portfolio Dynamics: RTW's stake in Cogent now represents 2.7% of its 13F reportable AUM, while its top holdings like MDGL and INSM also show robust market performance, highlighting the diversity of its investment strategy.
- Clinical Success Outlook: Cogent Biosciences' stock price surged 360% over the past year, and with its lead candidate's FDA application accepted, a crucial decision is expected by late 2026, which could further propel the stock's upward trajectory.
See More
RTW Investments Increases Stake in Cogent Biosciences
- Share Increase Details: RTW Investments added 4,124,755 shares of Cogent Biosciences in Q4 2026, with an estimated trade value of $115.95 million, indicating strong confidence in the company's future prospects.
- Holding Value Growth: By quarter-end, RTW's total holdings reached 7,592,241 shares valued at $269.68 million, reflecting a $219.88 million increase, which underscores market recognition and appreciation of Cogent's stock.
- Company Financial Health: Cogent Biosciences ended the year with approximately $900 million on its balance sheet, providing sufficient runway into 2028 while advancing multiple regulatory filings related to its lead drug, showcasing its robust R&D capabilities.
- Market Outlook Analysis: Despite a 360% surge in Cogent's stock price, its competitive edge in precision medicine and upcoming FDA decisions could yield substantial returns for investors, indicating significant future growth potential.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48.38 Million
- Share Reduction Details: Kynam Capital disclosed in a February 17, 2026 SEC filing that it sold 1,720,949 shares of Cogent Biosciences, translating to an estimated $48.38 million trade, indicating a disciplined approach to risk management while maintaining a significant position.
- Asset Management Proportion: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, remaining the fund's largest single position, which reflects ongoing confidence in the company's growth potential despite the reduction.
- Market Performance: As of last Friday, shares of Cogent Biosciences were priced at $33.38, having surged 360% over the past year, significantly outperforming the S&P 500's 15% gain, highlighting its strong market presence and investor interest in the biotech sector.
- Financial Status and Outlook: Cogent ended 2022 with $900.8 million in cash and equivalents, sufficient to fund operations into 2028, while its product bezuclastinib received FDA acceptance, with a target action date of December 30, further bolstering market confidence in its future prospects.
See More
